Impact of achieving euthyroidism on pulmonary artery systolic pressures in hyperthyroidism-associated pulmonary hypertension - a systematic review.

• Authors: Shireen R Chacko, Albert Einstein Medical Cente; Pradhum Ram, Emory University Hospital; Tamaryn Fox, Albert Einstein Medical Center; Naveen Sooknanan, Albert Einstein Medical Center; Kevin B Lo, Albert Einstein Medical Center P; Ritesh G Menezes, King Fahd Hospital of The University; Savita Lasrado, Father Muller Medical College Mangalore,; Glenn Eiger, Albert Einstein Medical Center P; Anjali Vaidya, Temple University Hospital
• Journal Title: Am J Cardiovasc Dis
• Volume: Volume 12, Number 4
• Publisher: (publisher) | 2022, Pages 212-223
• Type of Work: Article | Final Publisher PDF
• Subjects: Health Sciences, Pathology; Health Sciences, Medicine and Surgery
• Keywords: Hyperthyroidism; pulmonary hypertension

Abstract

In this systematic review, we seek to clarify the impact of treatment of hyperthyroidism on pulmonary hypertension in patients with both these conditions. We included 39 of 709 articles retrieved, that studied patients with hyperthyroidism and pulmonary hypertension (PH). From these, those with a documented pre-treatment Pulmonary Artery Systolic Pressure (PASP) > 35 mmHg and complete follow up were analyzed, yielding 3 case series and 22 case reports with a total of 81 cases. A significant improvement in PASP was noted with achieving euthyroidism in the 3 case series. The case reports showed a significant reduction in mean PASP from 60.5 ± 13.2 mmHg to 37.5 ± 10.1 mmHg (p < 0.001) in patients with Grave's disease with achieving euthyroidism. No deaths were reported during the follow up period. Achievement of a euthyroid state in patients with hyperthyroidism is associated with statistically significant reductions in PASP.